General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

Stiefel Laboratories acquires ABR Invent and ABR Development

May 8, 2008

Article

Coral Gables, Fla. - Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.

Coral Gables, Fla.

- Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.

Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both Invent and Development are based in France.

Atlean(R) is a bio-resorbable, sculpting and modeling dermal filler with hyaluronic acid and tricalcium phosphate particles. Atlean(R) received a CE-Mark granted in 2006 and is marketed in France and Italy, according to PRNewswire.